Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Want to see CTSO full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.04Last Year’s EPS
0.03Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced operational and commercial progress against near‑term financial and regulatory challenges. Positives include modest top-line growth, strong international direct momentum (+13% YoY), healthy gross margins (69%), improved adjusted profitability metrics, strengthening clinical evidence (STAR-T showing >50% reduction in severe bleeding), and clearer regulatory direction with two FDA breakthrough designations. Main negatives are the widened GAAP net loss driven by FX, lower cash balance (~$6.4M), a delayed de novo submission requiring additional mechanistic studies and resources (likely pushing approval into late 2026/early 2027), Germany market softness, and a $0.5M order disruption tied to geopolitical events. Overall, management is executing cost reductions and targeting operating cash flow breakeven in H2 2026, and the call conveyed cautious optimism despite the identified risks.Company Guidance
Modest Revenue Growth
Q1 2026 revenue of $8.9 million, up 2% year-over-year (down 7% on a constant currency basis), demonstrating resilience amid external headwinds.
Strong International Direct Performance
Direct international sales outside Germany grew 13% year-over-year, reflecting improved physician awareness, execution and adoption in key accounts.
Robust Installed Base and 2025 Volume
Core CytoSorb product sales exceeded $37 million in 2025 with over 300,000 devices used cumulatively in more than 70 countries, underscoring a large global installed base and recurring 'razor/razor‑blade' revenue model.
Improved Profitability Metrics (Adjusted)
Adjusted net loss improved to $3.4 million ($0.05/share) from $3.7 million ($0.06) prior year; adjusted EBITDA loss improved to $2.2 million from $2.7 million, indicating progress from cost reduction efforts.
Operating Expense and Cash Burn Improvement
Operating expenses decreased to $9.2 million from $10.1 million YoY following a strategic cost and headcount reduction (~10% in Q4 2025). Total cash burn improved to $1.1 million in the quarter (excluding $300k restructuring payments).
Strong Gross Margin and Working Capital Focus
Gross margin remained healthy at 69% (vs. 71% prior year). Management intentionally slowed production to reduce inventory to $4.8 million (from $5.3 million) to improve working capital efficiency.
Clinical Evidence and Regulatory Progress for DrugSorb-ATR
STAR-T randomized trial published in a leading cardiac surgery journal showing >50% reduction in composite severe bleeding with ticagrelor removal. DrugSorb-ATR retains two FDA Breakthrough Device designations and company has clear FDA direction on next steps (real‑world evidence + mechanistic data), enabling a defined regulatory path.
Commercial Enablers and Product Adoption
More than 100 PuriFi pumps placed internationally; HotSwap device launched and receiving positive feedback—both support adoption, dosing strategies, and broader usage across critical care and cardiac surgery.
Planned Path to Cash Flow Breakeven
Company targets achieving operating cash flow breakeven in the second half of 2026, supported by cost reductions and operational improvements.
CTSO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CTSO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $0.57 | $0.54 | -5.09% |
Mar 25, 2026 | $0.67 | $0.60 | -10.58% |
Nov 13, 2025 | $0.67 | $0.66 | -0.75% |
Aug 07, 2025 | $0.89 | $1.00 | +11.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cytosorbents Corp (CTSO) report earnings?
Cytosorbents Corp (CTSO) is schdueled to report earning on Aug 04, 2026, After Close (Confirmed).
What is Cytosorbents Corp (CTSO) earnings time?
Cytosorbents Corp (CTSO) earnings time is at Aug 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTSO EPS forecast?
CTSO EPS forecast for the fiscal quarter 2026 (Q2) is -0.04.